Possible Interaction: Buserelin and Progesterone

“The results proved, that the administration of buserelin to sterile women inhibits the ovarian (estradiol, progesterone ) and pituitary (LH, FSH) hormone secretion during the first 10-14 days of treatment.”

“Hence, in hyperstimulated cycles, 4-day treatment with buserelin caused profound endocrinological changes: namely, short-term rescue of the corpus luteum, prevention of an endogenous LH rise and premature luteinization and increased progesterone production in the early luteal phase.”

“In basal conditions, Buserelin , at 1 ng/ml, increased estradiol and progesterone (P) secretion, while at concentrations of 10 and 100 ng/ml, no effect was observed.”

“We have previously shown that intranasal administration of Buserelin (Hoechst AG, Frankfurt, Germany) at mid-luteal phase inhibits progesterone secretion and shortens the luteal phase.”

“In corpora lutea cultured in vitro, the GNRH1 analog buserelin ) reduced progesterone secretion and increased PGF2alpha secretion as well as PTGS2 and PGE2-9-K activities at mid and late stages.”

“ Buserelin in vivo treatment at days 9 and 13 decreased plasma progesterone levels for 48 and 24 h respectively.”

“In in vitro cultured CL, buserelin reduced progesterone secretion, increased prostaglandin F(2α) (PGF(2α)) secretion and cyclo-oxygenase-2 (COX-2) and nitric oxide synthase (NOS) activities at days 9 and 13, and decreased PGE₂ at day 13.”

“Although luteinizing-hormone (LH)-stimulated progesterone in both kinds of cells, buserelin significantly inhibited LH-stimulated progesterone only in luteoma cells.”

“ Progesterone concentrations increased (P<0.05) from 2 to 8h after buserelin treatment and returned to basal levels after 72 h, whereas oestradiol concentrations were maximal at 2h post-treatment and returned to basal levels after 24h (P<0.05).”

“In the tumor group, buserelin (100 ng/ml) inhibited human chorionic gonadotropin-induced cAMP and progesterone ; this effect was protein kinase C (PKC) dependent (inhibited by GF109203X, a PKC inhibitor).”

“The results of these trials confirmed the hypothesis that a strategic injection of the GnRH analogue, buserelin , could prevent the reductions in oestrous cycle length and conception rate associated with the chronic metoestrous administration of progesterone.”